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Background: Although many studies have assessed
poststroke objective cognitive impairment, only a few
have evaluated patients’ subjective cognitive complaints
(SCC). Although these SCC are found to be common in
the early and chronic phases after stroke, knowledge
about their risk factors, course over time, differences
with healthy controls and their diagnostic relevance is
limited. The aim of the COMPlaints After Stroke
(COMPAS) study is therefore to determine the possible
risk factors, prognosis, time course and predictive
value of SCC in the first 2 years after stroke.
Methods and design: A prospective cohort study is
conducted in which patients are compared to non-stroke
controls at 3, 6, 12 and 24 months after stroke.
Approximately 300 patients are recruited from the stroke
units of three hospitals in the Netherlands, while 300
controls are sought among the relatives (spouses excluded)
and social networks of participants. A wide range of
subjective and objective variables is assessed in both
groups using interviews, questionnaires and
neuropsychological assessment. The primary outcomes
include SCC and objective cognitive impairment, whereas
secondary outcomes are quality of life, subjective recovery
and daily life functioning.
Ethics and dissemination: The study is being carried
out in agreement with the Declaration of Helsinki and the
Medical Research Involving Human Subjects Act. The
protocol has been approved by the medical ethics
committees of the participating centres and all participants
give written informed consent. The results will be published
in peer-reviewed journals and disseminated to the medical
society and general public.
Discussion: The COMPAS study is the first to
systematically evaluate poststroke SCC in a prospective
longitudinal design, taking a wide range of subjective and
objective variables into account. The results obtained can
be used to accurately inform patients and their families,
as well as to develop patient-tailored intervention
programmes to ultimately improve stroke patient care.
BACKGROUND
Poststroke cognitive impairment is common
after stroke and can be evaluated either
objectively, using neuropsychological tests (ie,
objective cognitive performances (OCP)), or
subjectively, using interviews or self-report
questionnaires (ie, subjective cognitive com-
plaints (SCC)). Until now, the majority of
studies on poststroke cognitive sequelae have
focused on OCP without also evaluating
patients’ SCC. However, individuals’ perfor-
mances in test situations do not always corres-
pond to those in daily life and vice versa.1 2
Evaluating one can therefore not be used to
draw conclusions about the other.
In a recent systematic review, we found that
SCC are common in the early and chronic
phases after stroke and that they tend to
increase over time.3 The prevalence rates
vary between 28.6% and 92.0% and com-
plaints about memory, mental speed and
concentration were found to be those most
commonly reported.3 Furthermore, patients
and their proxies showed moderate agree-
ment on the prevalence and severity of
patients’ SCC.3 However, one of the main
problems in most of these studies is that
there is no ‘gold standard’ to define and
measure SCC, resulting in heterogenic find-
ings. In our review, we suggested that it is
important to differentiate between content of
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Strengths of this study are that it is the first pro-
spective cohort study on subjective cognitive
complaints in patients with stroke in which
patients and controls are evaluated at multiple
assessments, while at the same time a wide
range of subjectively and objectively measured
variables are taken into account.
▪ A limitation is that the most seriously affected
patients are unable to participate in the study.
This may reduce the generalisability of the
results to the stroke population as a whole.
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SCC (SCCc) and worrying about SCC (SCCw), as these
are two different concepts.3 The first focuses on the spe-
cific cognitive difficulties respondents say they experi-
ence, while the second indicates whether participants
find them worrisome, irritating and whether they say
they hinder daily life. A few studies have made this dis-
tinction so far.2 4 5 However, the majority of research on
poststroke SCC has evaluated SSCc and not SSCw, prob-
ably without being aware of the difference between
these aspects of SCC.3
Furthermore, we found in our review that poststroke
SCC are inconsistently associated with demographic and
clinical characteristics, current depressive symptoms and
OCP,3 but they may predict future emotional and cognitive
decline.5 6 However, most of the research on SCC after
stroke carried out so far is limited in that: unvalidated
methods for assessing SCC were used, there was no non-
stroke control group included, and the focus was on a spe-
cific subsample of stroke patients (eg, home-living patients
only), thereby impairing the generalisability of the results.
While SCC are common among stroke patients, knowledge
about the following aspects is only limited or practically
non-existent: the risk profile for developing SCC; their
course over time; their impact on quality of life (QOL),
subjective recovery and activities in daily life (ADL) func-
tioning; and their prognostic implications.
In the general non-stroke population, however, SCC
have been more frequently evaluated, in particular
memory-related SCC reported by the elderly.7 8 Factors
found to be associated with these complaints include:
demographic characteristics (higher age, women, lower
education), psychological distress, somatic symptoms,
personality traits (neuroticism in particular) and vascu-
lar risk factors.7–11 Furthermore, they are thought to be
clinically relevant in this group because of their associ-
ation with increased healthcare consumption, reduced
QoL, current OCP (this link is not always found) and
their predictive value for future cognitive decline.7 8 12
Whether this also applies to poststroke SCC is unknown.
More systematic research is therefore needed to gain
further knowledge about SCC among stroke survivors, to
be able to accurately inform patients and their relatives,
to develop adequate treatment programmes and to
ultimately improve poststroke care.
We therefore designed the COMPlaints After Stroke
(COMPAS) study in which we have four main aims:
▸ Determine the prevalence, profile and course over
time of SCCc and SCCw.
▸ Identify the risk profile for reporting SCC.
▸ Evaluate their predictive value for future cognitive
functioning.
▸ Determine the effect of SCC on QoL, subjective
recovery and ADL functioning.
Here we describe the design and protocol of the
COMPAS study, which is the first prospective cohort
study of SCC in patients with stroke, evaluating both
patients and controls, while at the same time a wide
range of variables is taken into account.
METHODS AND ANALYSIS
Design
A multicentre, prospective cohort study of patients with
stroke and controls is performed. We started in 2009
and the final measurements will be made in 2014.
Patients are evaluated five times, starting at the clinical
phase (T0), followed by an assessment at 3 months (T1),
6 months (T2), 1 year (T3) and 2 years (T4) after
stroke. Controls are seen at the same time intervals, start-
ing at T1.
Study population
Patients with stroke are recruited consecutively from the
stroke units of three hospitals in the Netherlands,
including the St Elisabeth and TweeSteden Hospitals in
Tilburg and the Maxima Medical Centre in Veldhoven.
The control group consists of a sample from the non-
stroke general population and is recruited among the
relatives and the social networks of participants in the
COMPAS study. Spouses of patients with stroke are
excluded from the control group since they are at a
higher risk of having physical, cognitive and psychosocial
problems themselves due to the fact that their partner
has suffered a stroke.13 14
Inclusion criteria
▸ Clinical diagnosis of a first or recurrent ischaemic or
haemorrhagic stroke (for patients only).
▸ At least 18 years old (no upper age limit).
Exclusion criteria
▸ Pre-existent health problems interfering with cogni-
tive functioning, including for example:
– Cognitive decline (as defined by a score >3.6 on the
short version of the Informant Questionnaire on
Cognitive Decline in the Elderly; IQCODE).15
– A recent history of severe psychopathology (eg,
suicide attempts, alcohol- or drug misuser, diag-
nosed personality or mood disorders).
– Severe physical comorbidity (eg, malignant diseases,
progressive neurological conditions).
▸ Severe communication difficulties (eg, insufficient
understanding of the Dutch language, severe aphasia,
blindness or deafness).
Procedure
Eligible patients receive oral and written information
about the study from their treating physician during the
clinical phase (T0). Demographic and clinical character-
istics are documented and patients are scheduled for
the first assessment 3 months after stroke (T1), during
which written informed consent is obtained for inclu-
sion to be definite. Participants acknowledge that they
have the intention to complete all four assessments, and
that they are allowed to end their participation at any
time. For the follow-up assessments (T2–T4), patients
are informed by letter and telephone and invited to par-
ticipate after which an appointment is scheduled.
Potential controls receive oral and written information
about the study from the researcher after which they are
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asked to participate in the study. The rest of the proced-
ure is the same as that for the patient group.
The assessments are administered in a standardised
way by trained neuropsychologists and take place at the
participating hospitals or, when this is not possible, at
the participant’s home or residence (eg, rehabilitation
centre).
Measures
Tables 1 and 2 give an overview of the variables assessed
and instruments used at each time point.
Outcomes
Primary outcomes of the COMPAS study are SCC and
OCP. To measure SCC, two instruments are used,
namely: the Dutch version of the Cognitive Failures
Questionnaire (CFQ)16 17 and the Checklist for
Cognitive and Emotional consequences following stroke
(CLCE-24).5 The CFQ focuses on SCCc and asks sub-
jects to rate 25 items on the frequency of cognitive slips
and errors in daily life on a 5-point Likert scale ranging
from 0 (never) to 4 (very often). SCCw is evaluated by
four additional general questions regarding the subject-
ive increase of complaints over time, the degree to
which these hinder daily life, are annoying and are a
source of concern. Each of these extra items is rated on
a scale ranging from 1 (not at all) to 5 (extremely).
The CLCE-24 is a structured clinical interview devel-
oped to evaluate SCCc and SCCw among stroke survi-
vors.5 It consists of 13 items concerning cognitive
complaints and 9 items addressing emotional and
behavioural complaints. Each item is scored as 0 (not
present), 1 (doubtful), 2 (present, but not affecting
daily life) or 3 (present and negatively affecting daily
life).
OCP are evaluated using an extensive neuropsycho-
logical assessment covering multiple cognitive domains
and containing traditional (eg, Rey Complex
Figure Test18) and more ecologically valid tests (eg,
Rivermead Behavioural Memory Test19). See table 1 for
an overview of all OCP tests used. In Spreen and
Straus20 and Lezak et al,21 a detailed description of each
of the instruments we use is given.
Secondary outcomes include QoL, ADL functioning
and subjective stroke recovery. Generic QoL is evaluated
using the short version of the self-report WHO Quality
of Life Questionnaire (WHOQOL-Bref)22 (26 items)
and, because we expect the majority of our population
Table 1 Primary and secondary outcomes in the COMPAS study
Instrument T0 T1 T2 T3 T4
Primary outcomes
SCC Cognitive Failures Questionnaire16 17 X X X X
Checklist for Cognitive and Emotional Consequences5 X X X X
OCP20 21
Global cognitive functioning Mini-Mental State Examination X X X
Visual perception and
construction
Rey Complex Figure Test—copy trial X X X
Mental speed/attention Stroop Colour word test—cards 1 and 2 X X X
Digit Symbol-Coding X X X
Episodic memory Rivermead Behavioural Memory Test X X X
Rey Complex Figure Test—immediate and delayed recall
trials
X X X
Verbal Paired Associates X X X
Working memory Digit span Forward and Backward conditions X X X
Language Boston Naming Test—short version X X X
Executive functioning Controlled Oral Word Association Test—FAS X X X
Category Fluency Test: animals and occupations X X X
Stroop Colour Word Test—card 3 X X X
Rule Shift Cards X X X
Zoo Map X X X
Fine motor dexterity Purdue Pegboard X X X
Secondary outcomes
Quality of Life WHO Quality of Life Questionnaire—short form22 X X X
WHO Quality of Life Questionnaire—Old module23 X X X
ADL functioning
Basic ADL Barthel index25 P X X X X
Instrumental ADL Frenchay Activities Index26 X X X X
Subjective stroke recovery Item 9 of Stroke Impact Scale24 P P P
ADL, activities in daily life; C, control group only; COMPAS, COMPlaints After Stroke; OCP, objective cognitive performance; P, patient
group only; SCC, subjective cognitive complaints; T0, clinical phase; T1, 3 months poststroke; T2, 6 months poststroke; T3, 1 year
poststroke; T4, 2 years poststroke; X, instrument used in both patients and controls.
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to be elderly (>60 years), the additional OLD module
(WHOQOL-OLD)23 comprising 24 items. While the first
covers overall well-being on the domains ‘physical’, ‘psy-
chological’, social relationships’ and ‘environment’, the
OLD module evaluates aspects of life which are specific
to the elderly, including: ‘intimacy’, ‘sensory abilities’,
‘autonomy’, ‘activities in the past, present and future’,
‘social participation’ and ‘dying’.
Subjective recovery after stroke is determined by a
single item from the Stroke Impact Scale,24 in which
patients are asked to indicate on a scale ranging from 0
(‘no recovery’) to 100 (‘full recovery’) how much they
feel they have recovered from their stroke.
ADL functioning is assessed in basic activities, includ-
ing self-care and mobility, using the Barthel Index25 (10
items) and more complex activities like housekeeping,
hobbies and employment, using the Frenchay Activities
Index26 (15 items).
All instruments chosen are frequently used (inter)
nationally in research and daily clinical practice dealing
with stroke patients.
Possible determinants
Depending on the specific outcome considered, SCC,
OCP, QoL, subjective recovery and ADL functioning are
either dependent or independent variables. A wide range
Table 2 Possible determinants in the COMPAS study
Variable/instrument T0 T1 T2 T3 T4
Demographic variables Age, gender, education, marital status, living situation, residence,
employment status, hand preference
P X X X X
Clinical characteristics
Stroke-specific Lifetime history of stroke, type, side, classification according to the
Oxford Community Stroke Project,27 severity within 24 h after admission
using the National Institutes of Health Stroke Scale,28 treatment,
poststroke complications, length of hospital stay, discharge destination
P
General Vascular risk factors, comorbidity (Cumulative Illness Rating Scale29),
(re-) admissions to hospital, medication use, current participation in
rehabilitation therapy
X X X X
Health status 12-Item Short Form Health Survey30 X X X
Premorbid status
Cognitive decline Informant Questionnaire on Cognitive Decline in the Elderly—short
form15
P C
IQ estimation Dutch version National Adult Reading Test31 X





Self-made item: ‘‘in the previous months (before your stroke), have you
experienced depressive complaints?”
P C






Hospital Anxiety and Depression Scale—subscale depression32 X X X X
Anxiety complaints Hospital Anxiety and Depression Scale—subscale anxiety32 X X X X
Fatigue Fatigue Assessment Scale33 X X X X
Stress Perceived Stress Scale, 4-item version34 X X X
Personal factors X X X
Coping style Utrecht Coping List—15-item version35 X
Personality trait—
neuroticism





Eysenck Personality Questionnaire Revised Short Scale—Extraversion
subscale36
X
Type D Type D scale-1437 X
Participants’
awareness of SCC
Cognitive Failures Questionnaire completed by proxy X X X X
Checklist for Cognitive and Emotional Consequences completed by
proxy
X X X X
Life events Self-made item concerning the presence and impact of a positive or
negative life event: “Last year, did something happen in your life which
had a major impact on you? This may be something either pleasant or
sad”
X X X
C, control group only; P, patient group only; SCC, subjective cognitive complaints; T0, clinical phase; T1, 3 months poststroke; T2, 6 months
poststroke; T3, 1 year poststroke; T4, 2 years poststroke; X, instrument used in both patients and controls.
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of possible determinants are additionally taken into
account, based on what is currently known from the lit-
erature on SCC in the general and the stroke population.
These include: demographic variables, clinical character-
istics (those related to stroke included) and health status;
premorbid status (ie, cognitive decline, IQ, cognitive and
emotional complaints); comorbid complaints about
mood (ie, anxiety and depression), fatigue and stress;
personal factors (ie, coping style, personality traits and
SCC awareness), and the occurrence and impact of posi-
tive and/or negative live events. See table 2 for the spe-
cific variables assessed and instruments used.
Planned statistical analyses
Cross-sectional analyses will be used to evaluate group dif-
ferences at each of the individual time points (T1–T4) and
include: χ2 test for categorical variables, the Mann-Whitney
U test for ordinal data, and the Student t test or (multivari-
ate) analysis of variances ((M)ANOVA) for continuous
dependent variables. Furthermore, differences across the
time points will be analysed using multilevel analysis, which
allows inclusion of all available data (ie, also those from
participants with partly missing values).
The course of SCC over time (T1–T4) will subse-
quently be evaluated using latent class growth analysis.
We will explore whether groups with different trajector-
ies of SCC over time can be distinguished and, if so,
what their characteristics are.
The predictive value of the determinants for the
primary and secondary outcome measures (ie, SCC, OCP,
QoL, subjective recovery and ADL functioning) at T3
and T4 will be determined using multivariate regression
analysis. Potential predictors are defined as variables with
at least a marginally significant association (p<0.10) with
the outcome. Only these variables will be included in the
subsequent regression analyses to determine the most
important predictors. In general, effects with a two-tailed
p<0.05 are considered statistically significant.
Sample size and power calculation
The sample size needed in the COMPAS study is calcu-
lated using the method for multilevel analysis according
to Twisk.38 Based on a high intraindividual correlation
across the different time points (r=0.70), an α level of
0.05 and power of 0.80, there are 180 participants per
group needed to be able to detect a small difference (at
least 0.2 SD) between the groups. We expect about 40%
drop-outs during the 2-year follow-up period due to
mortality, comorbidity or refusal to continue participa-
tion. Therefore, we aim to include 300 participants at




The COMPAS study is conducted in accordance with the
‘Helsinki Declaration’ (Seoul revision, 2008) and the
‘medical Research Involving Human Subjects Act’
(WMO). The study is non-invasive, imposes no risk on
participants, and its protocol has been approved by the
medical ethical committees of all participating hospitals
(ie, St. Elisabeth and TweeSteden Hospitals in Tilburg,
and the Maxima Medical Centre in Veldhoven), and has
been registered by the Central committee on Research
Involving Human Subjects (number NL31208.008.10).
Furthermore, written informed consent is obtained from
all participants.
Dissemination
The results obtained will be disseminated to the scien-
tific, medical and general public by publication in
national and international peer-reviewed journals, as
well as by presentations in conferences and meetings
with clinicians dealing with patients with stroke.
DISCUSSION
The COMPAS study is the first in which poststroke SCC
are systematically evaluated over time, while a wide
range of subjective and objective variables in patients
and controls is taken into account. While numerous
studies have measured poststroke OCP, only a few have
also evaluated the patients’ SCC. Also, while these symp-
toms are found to be common among patients with
stroke, knowledge about their risk factors, their course
over time, differences with the non-stroke population
and their predictive value for future functioning is prac-
tically non-existent.
Strong elements of the COMPAS study are its pro-
spective design with multiple assessments during the
first two years after stroke, and the extensive evaluations
of subjective and objective variables, which, based on
the current literature, are potentially relevant to SCC
after stroke. This gives us the opportunity to determine
a detailed risk profile for experiencing poststroke SCC.
Furthermore, the instruments chosen are widely
accepted and frequently used in daily clinical practice
dealing with patients with stroke. Traditional neuro-
psychological and more ecologically valid tests (eg, the
Rivermead Behavioural Memory Test) are used to evalu-
ate OCP, making it possible to determine whether the
ecological validity of tests affects the association between
SCC and OCP. Also, a healthy control group is assessed
at the same time points as the patients and will be used
as a reference group. This enables us to distinguish post-
stroke SCC in their prevalence, profile and time course
from, for example, factors which are associated with
ageing. A potential limitation of the study is that the
most seriously affected patients with stroke are unable to
participate, thereby reducing the possibility to generalise
the results to the stroke population as a whole. However,
our study differs from those carried out until now in this
field in that we include a broad selection of patients
with stroke, not only first-ever strokes or patients dis-
charged home.
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In conclusion, we feel that the COMPAS study has the
potential to contribute to knowledge on poststroke SCC.
Owing to the ageing population and healthcare
improvements, the number of stroke survivors who will
have to deal with poststroke impairment will increase in
the future, and the social and economic burdens will
rise accordingly.39 40 Clinicians are frequently con-
fronted with patients having SCC after their stroke, but
the meaning and relevance of these SCC have yet to be
determined. We aim to elucidate the possible risk
factors, prognosis and the predictive value of poststroke
SCC. This information can subsequently be applied by
clinicians in daily practice in order to more accurately
inform patients and their proxies and to treat SCC. Our
data may also prove useful in the future development of
patient-tailored intervention programmes to ultimately
improve individual stroke patient-centred care, which is
the ultimate aim of the COMPAS study.
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